| Today’s Big NewsOct 13, 2023 |
| By Angus Liu Bristol Myers Squibb’s Zeposia is no longer the only S1P receptor modulator on the market for ulcerative colitis, thanks to an FDA approval for what appears to be a more effective drug from Pfizer. |
|
|
|
By James Waldron Roche has claimed the latest phase 2 readout for its multiple sclerosis drug backs up the BTK inhibitor’s "best in disease" potential by achieving the "holy grail" in biopharma: crossing the blood-brain barrier. |
By Andrea Park Hot on the heels of handing down a trio of Class I labels this year to safety events concerning certain Abiomed heart pumps, the FDA has gone a step further in its crackdown. |
By Angus Liu The popular diabetes med Ozempic and its sister weight-loss drug Wegovy are boosting Novo Nordisk to new highs again and again. |
|
Wednesday, October 18, 2023 | 11am ET / 8am PT Join industry experts for an exciting glimpse into the future of pharmaceutical innovation! Gain a comprehensive understanding of the latest strategies in organofluorine-based drug synthesis and learn key insights for staying ahead of the curve in this rapidly evolving landscape. Register now.
|
|
By Conor Hale Parminder “Parry” Bhatia was named chief AI officer of GE HealthCare earlier this year after six years at Amazon and AWS working on its machine learning and generative AI programs. |
By Nick Paul Taylor Relay Therapeutics has decided to extend its race to market. Citing the impact of the Inflation Reduction Act (IRA), the biotech has paused plans to bring lirafugratinib to market in a rare cancer, choosing instead to pursue a larger, tumor-agnostic opportunity. |
By Zoey Becker Europe's drug regulator wasn't swayed by Amylyx's phase 2 data. The European Commission will make the final call on the drug's approval in the bloc by the end of the year. |
By Max Bayer CUNY is once again pinning its misfortunes on short-sellers, suggesting they were involved in leaking a CUNY report outlining scientific misconduct from a key scientific adviser. |
By Nick Paul Taylor Sotio Biotech has dealt another blow to attempts to establish cytokines as a cornerstone of cancer care, scrapping ongoing studies of its IL-15 superagonist after seeing insufficient efficacy in the clinic. |
By Andrea Park The new parameter has been available in Europe for a couple of years, since Masimo earned CE mark clearance in 2021 for a patient monitoring device with 12 sensors that included one to calculate what the company has dubbed ORi. |
Fierce podcastsDon’t miss an episode |
| In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation. They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease. |
|
|---|
|
|
|
November 14-15, 2023 | Free Virtual Event The Fierce Diversity, Equity, and Inclusion Forum is back again this year and better than ever. We are collaborating with our Fierce Healthcare Editorial Team to expand the topics and audience for this exciting program across two days. Providing a wide range of strategies and best practices for pharma and biotech companies looking to improve their diversity efforts across all areas of their business.Register now!
|
|
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| WhitepaperCell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
| WebinarEmbark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
| WhitepaperEconomic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
| WhitepaperFrom Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperLearn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| |
|
